PCN145 COST-EFFECTIVENESS ANALYSIS OF DURVALUMAB IN ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION IN FRANCE

Autor:	S. Roze, A. Zang, H. Haug, Christos Chouaid, M. Caillon, A. Tetafort, A. Gherardi, C. Le Péchoux
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Durvalumab Adult patients business.industry Health Policy Public Health Environmental and Occupational Health Locally advanced Cost-effectiveness analysis medicine.disease Internal medicine medicine Non small cell Lung cancer business
Zdroj:	Value in Health. 22:S463
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.341
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9797f74c60c3f81ebc9c80f36d9abe10 https://doi.org/10.1016/j.jval.2019.09.341 Zobrazit plný text záznamu Full Text from ScienceDirect